NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study.
about
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.Methylphenidate use and school performance among primary school children: a descriptive study.A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting.The use of methylphenidate hydrochloride extended-release oral suspension for the treatment of ADHD.Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.New Formulations of Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder: Pharmacokinetics, Efficacy, and Tolerability.Efficacy, Safety, and Tolerability of a Novel Methylphenidate Extended-Release Oral Suspension (MEROS) in ADHD.Methylphenidate extended-release oral suspension for the treatment of attention-deficit/hyperactivity disorder: a practical guide for pharmacists.Effect of Food Intake on the Pharmacokinetics of a Novel Methylphenidate Extended-Release Oral Suspension for Attention Deficit Hyperactivity Disorder.Optimization of Methylphenidate Extended-Release Chewable Tablet Dose in Children with ADHD: Open-Label Dose Optimization in a Laboratory Classroom Study.Methylphenidate HCL for the treatment of ADHD in children and adolescents.The use of modified-release methylphenidate in the treatment of attention-deficit/hyperactivity disorder.
P2860
Q22061981-0DBFAABB-5E12-4F2B-A7DA-175F94222ED6Q34394522-E86299E0-42EB-497F-9481-AA8834C1CD5CQ36327312-EA79A210-C411-4A00-8EEB-D5FF611B2496Q37190656-050EC32D-98EC-4D18-B169-E08B20C5CCFEQ37667633-8E4373E6-28D1-41E4-BC36-9B43B4D038A6Q38140019-9E73E6B6-5973-404C-95E0-84523F15AD77Q38376209-2303D4DB-7309-49CF-BC22-B8620521FE88Q38764857-8C1B01DB-D85C-46B0-9212-58C9800B4919Q48103802-BE087708-CE31-4AE7-9848-588F81BA1CBAQ49187017-AE48D8B2-6EDD-4FB3-84EC-8D2F5BE80A02Q50578470-8E063AE9-C68B-4396-B8C2-F2ACF0212E36Q52594335-DDC1E962-C6A8-4B93-835E-DE61BBCF04A8Q53736992-4A0F189C-A12E-4162-9E83-1AD6AF653DDDQ53757106-C973C583-5187-492D-BAFD-D33FD56F3698
P2860
NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
NWP06, an extended-release ora ...... a laboratory classroom study.
@en
type
label
NWP06, an extended-release ora ...... a laboratory classroom study.
@en
prefLabel
NWP06, an extended-release ora ...... a laboratory classroom study.
@en
P2093
P2860
P356
P1476
NWP06, an extended-release ora ...... a laboratory classroom study.
@en
P2093
Ann C Childress
Heidi W Belden
Sally A Berry
Sharon B Wigal
P2860
P356
10.1089/CAP.2012.0073
P577
2013-01-05T00:00:00Z